WallStreetZenWallStreetZen

NASDAQ: TPST
Tempest Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TPST stock forecasts and price targets.

Forecast return on equity

Is TPST forecast to generate an efficient return?

Company
-1,635.25%
Industry
21.34%
Market
151.33%
TPST's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TPST forecast to generate an efficient return on assets?

Company
-125.06%
Industry
-7.18%
TPST is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TPST earnings per share forecast

What is TPST's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.37
Avg 2 year Forecast
-$1.23
Avg 3 year Forecast
-$0.91

TPST revenue forecast

What is TPST's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$4.4M

TPST vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TPST$0.86N/AN/A
ICU$3.18$8.00+151.57%Strong Buy
CALC$0.84$10.00+1,090.48%Buy
AIXC$0.67N/AN/A
COCP$0.87N/AN/A
View Top Biotech Stocks

Tempest Therapeutics Stock Forecast FAQ

What is TPST's earnings growth forecast for 2026-2028?

(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.59%.

Tempest Therapeutics's earnings in 2026 is -$43,098,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$20,238,203, with the lowest TPST earnings forecast at -$19,444,548, and the highest TPST earnings forecast at -$20,833,445. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$18,274,796, with the lowest TPST earnings forecast at -$17,558,137, and the highest TPST earnings forecast at -$18,812,290.

In 2028, TPST is forecast to generate -$13,441,792 in earnings, with the lowest earnings forecast at -$12,914,663 and the highest earnings forecast at -$13,837,139.

If you're new to stock investing, here's how to buy Tempest Therapeutics stock.

What is TPST's revenue growth forecast for 2026-2028?

(NASDAQ: TPST) Tempest Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 48.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.94%.

Tempest Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast TPST's revenue for 2026 to be $0, with the lowest TPST revenue forecast at $0, and the highest TPST revenue forecast at $0. On average, 3 Wall Street analysts forecast TPST's revenue for 2027 to be $0, with the lowest TPST revenue forecast at $0, and the highest TPST revenue forecast at $0.

In 2028, TPST is forecast to generate $64,943,489 in revenue, with the lowest revenue forecast at $62,396,685 and the highest revenue forecast at $66,853,591.

What is TPST's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: TPST) forecast ROA is -125.06%, which is lower than the forecast US Biotechnology industry average of -7.18%.

What is TPST's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TPST) Tempest Therapeutics's current Earnings Per Share (EPS) is -$6.01. On average, analysts forecast that TPST's EPS will be -$1.37 for 2026, with the lowest EPS forecast at -$1.31, and the highest EPS forecast at -$1.41. On average, analysts forecast that TPST's EPS will be -$1.23 for 2027, with the lowest EPS forecast at -$1.19, and the highest EPS forecast at -$1.27. In 2028, TPST's EPS is forecast to hit -$0.91 (min: -$0.87, max: -$0.93).

What is TPST's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: TPST) forecast ROE is -1,635.25%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.